Current clinical application of dantrolene sodium
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Hong Seuk | - |
dc.contributor.author | Choi, Jae-Moon | - |
dc.contributor.author | In, Junyong | - |
dc.contributor.author | Sung, Tae-yun | - |
dc.contributor.author | Kim, Yong Beom | - |
dc.contributor.author | Sultana, Shofina | - |
dc.date.accessioned | 2023-08-01T01:40:10Z | - |
dc.date.available | 2023-08-01T01:40:10Z | - |
dc.date.created | 2023-08-01 | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 1975-5171 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88671 | - |
dc.description.abstract | Dantrolene sodium (DS) was first introduced as an oral antispasmodic drug. However, in 1975, DS was demonstrated to be effective for managing malignant hyperthermia (MH) and was adopted as the primary therapeutic drug after intravenous administration. However, it is difficult to administer DS intravenously to manage MH. MH is life-threatening, pharmacogenomically related, and induced by depolarizing neuromuscular blocking agents or inhalational anesthetics. All anesthesiologists should know the pharmacology of DS. DS suppresses Ca2+ release from ryanodine receptors (RyRs). RyRs are expressed in various tissues, although their distribution differs among subtypes. The anatomical and physiological functions of RyRs have also been demonstrated as effective therapeutic drugs for cardiac arrhythmias, Alzheimer’s disease, and other RyR-related diseases. Recently, a new formulation was introduced that enhanced the hydrophilicity of the lipophilic DS. The authors summarize the pharmacological properties of DS and comment on its indications, contraindications, adverse effects, and interactions with other drugs by reviewing reference articles. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한마취통증의학회 | - |
dc.relation.isPartOf | Anesthesia and Pain Medicine | - |
dc.title | Current clinical application of dantrolene sodium | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.17085/apm.22260 | - |
dc.identifier.bibliographicCitation | Anesthesia and Pain Medicine, v.18, no.3, pp.220 - 232 | - |
dc.identifier.kciid | ART002982181 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85166514190 | - |
dc.citation.endPage | 232 | - |
dc.citation.startPage | 220 | - |
dc.citation.title | Anesthesia and Pain Medicine | - |
dc.citation.volume | 18 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Kim, Yong Beom | - |
dc.subject.keywordAuthor | Adverse events | - |
dc.subject.keywordAuthor | Dantrolene | - |
dc.subject.keywordAuthor | Malignant hyperthermia | - |
dc.subject.keywordAuthor | Pharmacology | - |
dc.subject.keywordAuthor | Ryanodine receptor calcium release channel. | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.